Patient Ambulation Articles & Analysis
-
Welcome T2
A complete redesign of the T-Stat was launched in 2020. New features included a sleek and strong exterior of powder coated metal, framed with a soft plastic bumper to prevent any damage in the hospital environment. Battery back-up was added to make patient ambulation and transfer seemless and without any interruption in patient data. WiFi access has been added to accommodate hospitals and labs ...
-
BioTrace Medical Announces Key Events Featuring Tempo Temporary Pacing Lead at TVT 2019
BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the Annual Transcatheter Valve Therapy Structural Heart Summit (TVT 2019), which will take place June 12-15 at the Sheraton Grand Chicago. The company’s Tempo Temporary Pacing Lead will be featured in a symposium titled “Improving Safety & Reducing ...
-
BioTrace Medical Announces Key Events Featuring Tempo Lead at TCT 2018
BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the 30th annual Transcatheter Cardiovascular Therapeutics (TCT) conference, which will take place September 21-25 in San Diego. BioTrace Medical’s innovative Tempo Temporary Pacing Lead is designed for secure and stable pacing with the goal of reducing ...
-
BioTrace Medical Announces Key Events Featuring Tempo Temporary Pacing Lead at TCT 2017
BioTrace Medical, Inc., today announced the company’s key activities at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 meeting, which will take place October 29 - November 2 at the Colorado Convention Center in Denver. The company’s Tempo Temporary Pacing Lead will be featured in a breakfast symposium titled: “The Tempo Temporary Pacing Lead: A New Standard of Care in ...
-
Experience with BioTrace Medical’s Tempo Temporary Pacing Lead in Mitral Valve Surgeries Presented at Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting
BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company’s Tempo Temporary Pacing Lead was featured in a patient case series presented at the Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting and Workshops, taking place virtually April 24-27. The series titled “A Case Series of the BioTrace Medical Tempo ...
-
BioTrace Medical Announces Key Events Featuring Tempo Temporary Pacing Lead at TCT 2019
BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) conference, which will take place September 25-29 in San Francisco. The company’s Tempo Temporary Pacing Lead will be featured in a breakfast symposium titled “Keeping the Rhythm with the ...
-
Transluminal Technologies completes the First-in-Man study of the velox LB vascular closure device
Asuncion, Paraguay, April 20, 2017 – Transluminal Technologies, LLC, a Syracuse, NY-based medical device company has announced today that they have successfully completed the First-in-Man clinical study of the velox LB large bore vascular closure device with 100% procedural success (10/10). Methods: Patients with a baseline common femoral artery (CFA) diameter of ≥ 6.0 mm were ...
-
Cardiva Medical Announces Positive Results of the AMBULATE Pivotal Study Evaluating the VASCADE MVP System Compared to Manual Compression for Multi-Vessel Closure Following Electrophysiology Procedures
The AMBULATE pivotal study met its primary efficacy endpoint. The median time to patients getting on their feet following arrhythmia ablation procedures was reduced by 3.9 hours. AMBULATE demonstrated that patients in the VASCADE MVP arm had significantly improved patient satisfaction and a significant reduction in the post-procedure use of opioid pain medications. Late-breaking results were ...
-
BioTrace Medical Announces Key Events Featuring Tempo Lead at TVT 2018
The company’s Tempo® Temporary Pacing Lead will be featured in a New Technology Forum discussion titled “Improved Temporary Transvenous Pacers: The BioTrace Tempo Lead,” presented by Steven Yakubov, M.D., System Chief, Advanced Structural Heart Disease at Riverside Methodist Hospital/OhioHealth. The discussion will highlight the performance and benefits of the Tempo Lead ...
-
BioTrace Medical’s Tempo Lead Obtains CE Mark for Safe and Secure Temporary Intracardiac Pacing
BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s Tempo Lead has obtained CE Mark certification in Europe for use in cardiac procedures requiring temporary intracardiac pacing. BioTrace Medical’s Tempo Temporary Pacing Lead is designed for safer, more secure and stable pacing to reduce intraprocedural complications, ...
-
Cardiva Medical Announces First Patients Enrolled in The AMBULATE Same Day Discharge Study Using VASCADE MVP
SANTA CLARA, Calif., July 16, 2020 -- Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the first patient enrollments in its AMBULATE Same Day Discharge study, the first prospective multi-center study designed to evaluate same-day discharge for patients undergoing cardiac ablation procedures for atrial fibrillation. The study is utilizing the VASCADE MVP Venous ...
-
Cardiva Medical Announces FDA Approval of the VASCADE MVP Vascular Closure System for Multi-Site Vessel Closure Following Electrophysiology Procedures
VASCADE MVP is the first vessel closure technology designed for electrophysiology procedures – and proven by electrophysiology physicians in a multi-center, randomized, controlled clinical trial. Potential procedures include cardiac ablation and left atrial appendage closure among others. Greater than 400,000 patients per year in the United States may benefit – with procedures ...
-
The Lancet Publishes Positive Results from Capricor Therapeutics` Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy
One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients Data Sets Stage for Pivotal Phase 3 HOPE-3 Clinical Trial Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention ...
-
FDA Clears Rex Medical Bioresorbable Vascular Closure Device
August 3, 2016 — The U.S. Food and Drug Administration (FDA) has granted market clearance to Rex Medical’s bioresorbable Closer Vascular Sealing System (VSS) to achieve rapid hemostasis of femoral artery catheterizations. The vascular closure device consists of an insertion sheath, dilator and an implant contained in a delivery system. It uses a patch placed against the artery wall ...
-
Axio Biosolutions receives another FDA clearance for Axiostat Patch for Vascular Bleeding Control
Axio Biosolutions, an integrated wound care company has announced FDA 510(k) clearance of its hemostatic product, Axiostat Patch that helps control moderate to severe bleeding in vascular procedures, surgical debridement sites, puncture sites and more. Axiostat Hemostatic Patch is based on a protonated bioadhesive technology which works by providing a strong mechanical barrier to the injury ...
-
CurvaFix Announces Participation in Orthopaedic Trauma Association Industry Sessions
BELLEVUE, Wash., Oct. 6, 2022 – CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced participation in the Industry Sessions of the Orthopaedic Trauma Association (OTA) 38th Annual Meeting, Oct. 12-15 in Tampa, Fl, highlighting the expanding use of the CurvaFix® IM Implant by industry-leading surgeons for both fragility and high-impact ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you